Our prior work suggested SAS1B as a candidate immunotherapeutic target with ADCs in uterine and pancreatic cancers.5 6 This current work demonstrates that SAS1B is a candidate immunotherapeutic target with ADCs in additional cancers including renal cell carcinoma, lung adenocarcinoma, and squamous cell lung cancer (figure 6). This evidence concerns the gene ASTL and cancer.